Who are Aceclidine ophthalmic solution's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Pilocarpine Ophthalmic Solution, Pilocarpine HCl, Xanomeline Enteric Capsule, Low dose pilocarpine.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/aceclidine-ophthalmic-solution.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-18 · How we verify

Aceclidine ophthalmic solution — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Aceclidine ophthalmic solution (Aceclidine ophthalmic solution) competitive landscape: 4 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Muscarinic receptor agonist. Area: Ophthalmology.

phase 3 Muscarinic receptor agonist Muscarinic acetylcholine receptors (M1, M3) Ophthalmology Small molecule Live · refreshed every 30 min

Target snapshot

Aceclidine ophthalmic solution (Aceclidine ophthalmic solution) — LENZ Therapeutics, Inc. Aceclidine is a cholinergic agonist that stimulates muscarinic receptors in the eye to increase accommodation and improve near vision.

Comparator set (4 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Aceclidine ophthalmic solution TARGET	Aceclidine ophthalmic solution	LENZ Therapeutics, Inc	phase 3	Muscarinic receptor agonist	Muscarinic acetylcholine receptors (M1, M3)
Pilocarpine Ophthalmic Solution	Pilocarpine Ophthalmic Solution	Maastricht University Medical Center	marketed	Muscarinic receptor agonist	Muscarinic acetylcholine receptor (M3)
Pilocarpine HCl	Pilocarpine HCl	Allergan	phase 3	Muscarinic receptor agonist	Muscarinic M3 receptor
Xanomeline Enteric Capsule	Xanomeline Enteric Capsule	Bristol-Myers Squibb	phase 3	muscarinic receptor agonist	M1, M4
Low dose pilocarpine	Low dose pilocarpine	Ocuphire Pharma, Inc.	phase 3	Muscarinic receptor agonist	Muscarinic acetylcholine receptors (M3, M4)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Muscarinic receptor agonist class)

Allergan · 1 drug in this class
LENZ Therapeutics, Inc · 1 drug in this class
Maastricht University Medical Center · 1 drug in this class
Ocuphire Pharma, Inc. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Aceclidine ophthalmic solution — Competitive Intelligence Brief. https://druglandscape.com/ci/aceclidine-ophthalmic-solution. Accessed 2026-05-18.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab